SkinBioTherapeutics PLC Result of AGM

RNS Number : 4635R

SkinBioTherapeutics PLC

27 December 2024

 

 

SkinBioTherapeutics plc

("SkinBioTherapeutics" or "the Group")

 

Result of Annual General Meeting

 

27 December 2024 - SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), a life science company focused on skin health, held its Annual General Meeting today and all resolutions were passed.

 

An electronic copy of the Annual Report and Accounts and the Notice of AGM will also be available on the Company's website - https://www.skinbiotherapeutics.com/investor-relations.

 

 

-Ends-

 

For more information please contact:   SkinBioTherapeutics plc Stuart J. Ashman, CEO Manprit Randhawa, CFO   Tel: [phone]       Cavendish Capital Markets Limited (Nominated Adviser & Broker) Giles Balleny, Dan Hodkinson (Corporate Finance) Charlie Combe (Broking) Dale Bellis, Tamar Cranford-Smith (Sales)   Tel: [phone] Vigo Consulting (financial press) Rozi Morris Tel: [phone] [e-mail] Notes to Editors About SkinBioTherapeutics plc SkinBioTherapeutics is a life science company focused on skin health. The Group's proprietary platform technology, SkinBiotix®, is based upon discoveries made by the translational dermatology team at the University of Manchester. The Group's foundation business is targeting the skin healthcare market via five pillars, the most advanced of which are cosmetic skincare (SkinBiotix) and food supplements to modulate the immune system by harnessing the gut-skin axis (AxisBiotix). The cosmetic pillar has a partnership with Croda plc and the Group's first in-house product, AxisBiotix-Ps™, is a food supplement to address the symptoms of mild to moderate psoriasis. The Group is also acting as a consolidator and is making acquisitions in complementary areas such as skin care and cosmetic applications, that also bring new distribution and geographical platforms, and manufacturing capabilities through which it can funnel its in-house pillar products.   The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit:www.skinbiotherapeutics.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

RAGQKOBPKBDDCBB